Skip to main content
Contact Us
Subscribe
E-Edition
32°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Travere Therapeutics, Inc.
< Previous
1
2
3
Next >
Travere Therapeutics to Present at Upcoming Investor Conferences
November 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ASX
CSLLY
TVTX
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
CSLLY
TVTX
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.